Discover

BHVN
Biohaven Ltd.
15.76
300 x undefined
400 x undefined
bid
ask
+
0.88
5.91%
350 @ 06:13 AM
15.88 +0.12 (0.76%)
Ytd39.59%
1y12.89%
14.59
day range
15.79
7.48
52 week range
18.57
Open14.95Prev Close14.88Low14.59High15.79Mkt Cap2.37B
Vol4.74MAvg Vol2.77MEPS-5.57P/EN/AForward P/E-8.09
Beta3.31Short Ratio8.46Inst. Own97.56%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0450-d Avg11.09200-d Avg11.581yr Est21.94

BHVN News

benzinga.com
Biohaven Completes Enrollment In RISE3 Trial To Evaluate Opakalim Channel Activator To Treat Refract

Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
prnewswire.com
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
benzinga.com
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
benzinga.com
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
benzinga.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

benzinga.com
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper

benzinga.com
Biohaven Announces Enrollment Of First Patient In Its Pivotal Phase 3 Trial Of BHV-1300 For Graves'

BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
prnewswire.com
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein De

BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne

benzinga.com
Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform Modulator

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f